Iambic Therapeutics, Inc (IAM) Stock
Key stats
- Market cap
- $729.26M
- Price / Earnings ratio
- -9.1x
- EPS (TTM)
- -$3.57
- Volume
- Loading
- 52-week high
- $25.00
- 52-week low
- $9.60
Source: third-party data provider, as of November 13, 2026
Recent news

Cathie Wood-Led Ark Loads Up On GOOG, AMD, NVDA And Biotech Stocks — But Sells CRWV, AVGO, LLY
Cathie Wood-Led Ark Loads Up On GOOG, AMD, NVDA And Biotech Stocks — But Sells CRWV, AVGO, LLY
IAM

Iambic Presents Updated IAM1363 Clinical Data at ESMO 2026, Showing Durable Responses with a Favorable Tolerability Profile in Heavily Pretreated Participants with HER2-Driven Cancers
Iambic Presents Updated IAM1363 Clinical Data at ESMO 2026, Showing Durable Responses with a Favorable Tolerability Profile in Heavily Pretreated Participants with HER2-Driven Cancers
IAM

Iambic Announces Pricing of Initial Public Offering
Iambic Announces Pricing of Initial Public Offering
IAM

Nvidia-backed Iambic Therapeutics targets up to $806 million valuation in US IPO
Nvidia-backed Iambic Therapeutics targets up to $806 million valuation in US IPO
IAM
News tone: automated (AI) classification of the article's content, not a price prediction.
Analyst ratings
Analyst consensus: Buy
Based on 3 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Cathie Wood-Led Ark Loads Up On GOOG, AMD, NVDA And Biotech Stocks — But Sells CRWV, AVGO, LLY
Cathie Wood-Led Ark Loads Up On GOOG, AMD, NVDA And Biotech Stocks — But Sells CRWV, AVGO, LLY
IAM

Iambic Presents Updated IAM1363 Clinical Data at ESMO 2026, Showing Durable Responses with a Favorable Tolerability Profile in Heavily Pretreated Participants with HER2-Driven Cancers
Iambic Presents Updated IAM1363 Clinical Data at ESMO 2026, Showing Durable Responses with a Favorable Tolerability Profile in Heavily Pretreated Participants with HER2-Driven Cancers
IAM

Iambic Announces Pricing of Initial Public Offering
Iambic Announces Pricing of Initial Public Offering
IAM

Nvidia-backed Iambic Therapeutics targets up to $806 million valuation in US IPO
Nvidia-backed Iambic Therapeutics targets up to $806 million valuation in US IPO
IAM

Docusign Declines 7.2% Since Beating Q1 Earnings & Revenue Estimates
Docusign Declines 7.2% Since Beating Q1 Earnings & Revenue Estimates
IAM
News tone: automated (AI) classification of the article's content, not a price prediction.
About Iambic Therapeutics, Inc
Iambic Therapeutics is a technology and clinical-stage life sciences company pursuing a fundamental shift in the biopharmaceutical industry. Its mission is to make better technology for better medicines. It does this by integrating leading proprietary, large-scale artificial intelligence (AI) with automated, scalable chemistry and biology experimentation.
Fundamentals
Valuation
Trading
Source: third-party data provider, as of November 13, 2026
Analyst views
3 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $22.00
- Average
- $29.00
- High
- $35.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -29.0 | +18.7 |



